Vincent Alcazer (@AlcazerVincent) profile picture

MD, Hematologist @CHUdeLyon | PhD in Immunology & Bioinformatics Myeloid malignancies (AML, MPN, AA, PNH) Looking for Human Endogenous Retroviruses everywhere

Lyon, France
Joined August 2020
Photo by Vincent Alcazer (@AlcazerVincent)Photo by Vincent Alcazer (@AlcazerVincent)Photo by Vincent Alcazer (@AlcazerVincent)Photo by Vincent Alcazer (@AlcazerVincent)Photo by Vincent Alcazer (@AlcazerVincent)Photo by Vincent Alcazer (@AlcazerVincent)Photo by Vincent Alcazer (@AlcazerVincent)Photo by Vincent Alcazer (@AlcazerVincent)Photo by Vincent Alcazer (@AlcazerVincent)Photo by Vincent Alcazer (@AlcazerVincent)
Looking for a free open-source software with a user-friendly graphical interface for data analysis? Consider using #StatAid! #RStats Online version: alcazerv.shinyapps.io/StatAi… Github: github.com/VincentAlcazer/St… Paper: joss.theoj.org/papers/10.211…
2
16
64
Vincent Alcazer retweeted
Gorgeous under the microscope, devastating in reality. A rare presentation of AML-MRC masquerading as Burkitt-like cells with a striking "starry-sky" pattern. Don't let the aesthetic fool you—the genetics tell a whole different story. @BloodPortfolio authors.elsevier.com/a/1nDF2…
1
2
69
Triplet therapy in FLT3-mut AML: ready for primetime? Key study signals👇 • VICEROY (Aza/Ven/Gilt): CRc ~90–91%; 12-mo OS 60–78%; median OS ~22–23 mo • Aza/Ven/Gilt frontline (n=30): CR+CRi 96%; FLT3-ITD MRD <10⁻⁵ ~65%; 1-yr OS 85% • HMA/Ven/FLT3i (n=88): Composite response 98%; median OS 28 mo; 3-yr OS 46% • Dec/Ven/Quiz (n=30): CRc 94%; 1-yr OS 72%, 2-yr OS 60% #ASH25 #AMLsm #leusm #MedTwitter @AML_Hub @ASH_hematology
24
98
5,171
In less than a month, the #ASH2025 Annual Meeting 🩸 kicks off! Our bioinformatics & AI research group 🖥️ will present 3 key studies this year — all bridging machine learning 🤖 and hematology 🔬. 👇 Highlights:
1
177
Menin inhibitors (MENi) are a major therapeutic hope for AML with specific molecular profiles. 🧬We performed transcriptomic profiling of MENi treated pts and identified a response-associated signature, shedding light on resistance mechanisms 🔎 🔗 meetings-api.hematology.org/…
1
1
98
See you in Orlando 🇺🇸 on Dec 5th for more discussions on applied AI 🤖 & bioinformatics 🖥️ in hematology 🩸! #ASH2025 #Hematology #ArtificialIntelligence #Bioinformatics #AI #Omic #RNAseq
124
A clinical guide to TP53 mutations in myeloid neoplasms ashpublications.org/blood/ar…
1
22
95
5,472
‘Raise the Bar’, a Canadian intervention to combat disparities in the recognition and management of iron deficiency: Development of the intervention, feasibility and implementation buff.ly/MfNzLff
5
11
1,025
Tumor Lysis Syndrome | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
2
77
TE-PARPi as a precision weapon against hematologic cancers ashpublications.org/blood/ar…
69
Interferons in health and disease: Cell cell.com/cell/fulltext/S0092…
1
14
1,496
Vincent Alcazer retweeted
How many platelets do I need to perform a safe lumbar puncture in patients with hematologic malignancies? 40 is the new 50! haematologica.org/article/vi…
3
107
4
305
26,571
Imaging mass cytometry reveals the order of events in the pathogenesis of immune-mediated aplastic anemia ashpublications.org/blood/ar…
1
7
14
1,447
How I treat acute lymphoblastic leukemia in the era of immunotherapy while revisiting the myth of second remission ow.ly/VNYF50WBFRq #HowITreat #lymphoidneoplasia #transplantation
20
69
4,867
Clonal haematopoiesis to clonal cytopenias: unravelling disease evolution over time - The Lancet Haematology thelancet.com/journals/lanha…
2
13
67
4,214